Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as β-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD.
Baker, K. E., Bonvini, S. J., Donovan, C., Foong, R., Han, B., Jha, A., ... Moir, L. M. (2014). Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models. Pulmonary Pharmacology and Therapeutics, 29(2), 181-198. https://doi.org/10.1016/j.pupt.2014.05.008